Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

France-Based Sartorius Stedim Plans Marlborough, Massachusetts, Bioprocess Operations

12/10/2024
France-based Sartorius Stedim Biotech, a biopharmaceutical company, has established operations in Marlborough, Massachusetts. The project is expected to create 120 jobs.

The 63,000-square-foot Center for Bioprocess Innovation features research and service laboratories, as well as facilities for customer demos and training.

"The Greater Boston area is home to an unparalleled ecosystem that fosters innovation, collaboration, and growth. As a global hub for biotechnology and life sciences, it offers access to world-renowned academic institutions, cutting-edge research facilities, and a highly skilled workforce. Moreover, the region's robust network of venture capital firms and industry partnerships provides ample opportunities for strategic collaborations. This is an ideal time and a great place to launch these capabilities which are so critical to the success of our customers," said Maurice Phelan, President of Sartorius North America.

Sartorius Stedim Biotech helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The company currently operates manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia.

"Massachusetts is the global epicenter of life sciences because of companies like Sartorius," noted Yvonne Hao, Massachusetts Secretary of Economic Development. "This new center will serve as a hub that encourages open collaboration and creates comprehensive research pathways for experts. We look forward to this company's continued success, and we are grateful for their work ensuring that our communities have access to innovative therapeutic technologies."

Exclusive Research